Efficacy of platelet rich plasma for bone union on lateral lumbar interbody fusion surgery using unidirectional porous beta-tricalcium phosphate - LLIF-PRP

Yamazaki Masashi0 个研究点目标入组 15 人开始时间: 2020年11月13日最近更新: 2024年5月27日

试验速览

暂无简介。

•1. Patients who receives lateral lumbar interbody fusion surgery for vertebral fracture, lumbar canal stenosis, lumbar spondylolisthesis, adult spine deformity, and so on
•2. Patients who receives lateral lumbar interbody fusion surgery at 1-4 levels
•3. Patients over 20 years old
•4. Patients with informed concent and understanding for treatment

•1. Patients with a history of lumbar surgery, purulent spondylitis, or spinal tumor
•2. Patients who received other Investigational new drug within 3 months of participating in this clinical study
•3. Patients who have a primary illness that is clearly inferior to bone formation (bone metabolic disease, dialysis, and so on)
•4. Patients who have uncontrolled diabetes
•5. Patients with anemia (Hb<9.0g/dL)
•6. Patients who have disorder of blood coagulation.
•7. Patients with rheumatoid arthritis who are using biologics with high risk of perioperative infection.
•8. Women who are pregnant or suspected ofbeing pregnant or breastfeeding
•9. Patients with metal allergy
•10. Patients who needs the legal representative
•11. Patients who are judged inappropriate by the responsible doctor for the study

发起方

Yamazaki Masashi